---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-109069"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2024-09-24T23:59:59+00:00"
generated_at: "2026-05-31T02:05:36.342902+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics reduces workforce from 80 to 51, expects $10M annual savings

## Summary
- Workforce reduction of 29 employees (36%) to focus on pociredir, DBA, and early discovery; suspends losmapimod.
- One-time severance costs of approximately $2 million expected in Q3 2024.
- Annual operating expense savings of about $10 million anticipated starting Q1 2025.
- Majority of costs incurred by September 30, 2024; implementation substantially complete by Q3 end.

## SEC filing metadata
- accession: 0000950170-24-109069
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2024-09-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000095017024109069/0000950170-24-109069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000095017024109069/fulc-20240924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-109069
- JSON: https://secwatch.observer/filing/0000950170-24-109069.json
- Plain text: https://secwatch.observer/filing/0000950170-24-109069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.